Emily M. Leproust

Twist Bioscience CEO Emily M. Leproust sold 18,880 shares at $95.00 under 10b5-1 plan; stock up 55.6% in 30 days.

Emily M. Leproust sold 18,880 shares at $95.00 on 2026-06-25, reducing her holdings from 842.9K to 824.0K shares, under a pre-arranged 10b5-1 trading plan adopted on 2025-05-27. The sale represents scheduled activity rather than a discretionary market decision. TWST has appreciated 55.6% over the preceding 30 days and 124.2% over the preceding 90 days, significantly outperforming her cross-ticker track record (average 30-day and 90-day returns of +14.1% and +14.6%, respectively after her prior 14 sells across all tickers). The company remains unprofitable with a net loss of $44.0M in the latest quarter, though revenue growth stands at 20.3% year-over-year. As a 10b5-1 execution, this transaction carries no inference about the executive's market timing or conviction at the point of filing.

TWST CEO Emily Leproust sells 16,470 shares for $1,118,554.58 via scheduled 10b5-1 plan; retains 846,872 shares + 75,439 options.

Emily M. Leproust, TWST CEO, executed 4 separate open-market sales totaling 16,470 shares for $1,118,554.58 on 2026-05-28 under a pre-arranged 10b5-1 trading plan adopted 2025-05-27. Prices ranged from $65.33 to $68.61 (blended average $67.91), near the current price of $67.86 and well above the 52-week low of $23.30. This is a 1.9% reduction of her non-derivative holdings, leaving her with 846,872 shares post-transaction. The sale follows modest near-term stock strength (+12.4% over 30 days, +45.5% over 90 days) but occurs at a company trading 4.5% below its 52-week high of $71.04. TWIST remains unprofitable (latest quarter net income $-44.0M) despite revenue growth of +20.3% year-over-year and latest quarterly revenue of $110.7M. Her prior sales at TWST have shown mixed near-term results (30-day returns: -8.2%, -7.2%, -9.5%, +1.8%, -2.1%), and her cross-ticker track record shows average 90-day return of +7.5% after sells. The scheduled nature of this sale under her 10b5-1 plan means the timing reflects pre-planned portfolio management rather than a discretionary decision responding to current conditions.

TWST CEO Emily Leproust sold 49,299 shares for $3,213,653.17 via 10b5-1 plan; retains 846,872 shares plus 208,835 option holdings.

CEO Emily M. Leproust executed 3 separate sales totaling 49,299 shares for $3,213,653.17 (blended average price $65.19) on May 26–27, 2026, as part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-27. This is a scheduled, non-discretionary transaction. Post-sale, she retains 846,872 non-derivative shares and 208,835 shares in derivative holdings (option pools), representing a -5.5% reduction in her non-derivative position. The current price of $69.03 is above the sale prices ($65.08–$66.28), reflecting a 16.7% gain in the stock over the past 30 days and +47.1% over 90 days. While her prior sales at TWST show mixed results (three recent sells in April 2026 followed by 30-day declines of -8.2%, -7.2%, and -9.5%), the structured nature of the 10b5-1 plan removes discretionary timing from this decision and positions it as a pre-planned liquidity event. The company remains unprofitable (net income $-44.0M on latest full-year basis) despite 20.3% annual revenue growth.

CEO Emily Leproust sold 9,671 shares at $65.24 blended average; stock now $58.85 (-6.9% from 52-week high), company unprofitable.

Emily Leproust, CEO of unprofitable Twist Bioscience, executed 3 separate sales totaling 9,671 shares for $630,957.35 across April 21-22, 2026, at prices ranging from $65.01 to $66.00. The stock has since declined to $58.85, 6.9% below its 52-week high of $63.20, suggesting the CEO may have sold near a local peak. Her cross-ticker track record shows a 0.00% well-timed sell rate (0 of prior 4 sells preceded subsequent 90-day declines), and at TWST specifically, 0 of 4 prior sales were well-timed at the 90-day mark—a consistent pattern of selling into strength rather than before downturns. She retains 858,887 shares post-transaction, a modest 1.1% reduction from her 868,558 share position. The company reported negative net income of $-30,507,000.00 on quarterly revenue of $103,698,000.00, indicating structural profitability challenges that merit investor attention despite 20.3% annual revenue growth.